Brequinar sodium
Based on 34 publication(s) in Google Scholar
Brequinar (sodium) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
For research use only. We do not sell to patients.
- Purity: 99.22%
- CAS No.: 96201-88-6
- Formula: C23H14F2NNaO2
- Molecular Weight:397.35
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Brequinar sodium
More- Nature. 2024 Feb;626(7998):411-418. [Abstract]
- Nature. 2022 Apr;604(7904):134-140. [Abstract]
- Nat Cell Biol. 2023 Jun;25(6):836-847. [Abstract]
- Acta Pharm Sin B. 2026 May 22.
- Adv Sci (Weinh). 2026 Jun;13(33):e21098. [Abstract]
- Adv Sci (Weinh). 2022 May 4;e2105451. [Abstract]
- J Adv Res. 2025 May 10:S2090-1232(25)00309-1. [Abstract]
- Sci Adv. 2025 Aug 15;11(33):eadx6587. [Abstract]
- Sci Adv. 2022 Sep 16;8(37):eabp9005. [Abstract]
- Redox Biol. 2024 May:71:103112. [Abstract]
- Redox Biol. 2023 Jun:62:102708. [Abstract]
- Cell Rep Med. 2025 Jan 27:101928. [Abstract]
- Nat Struct Mol Biol. 2024 May 20. [Abstract]
- J Colloid Interface Sci. 2026 Jul 15:714:140204. [Abstract]
- Cell Death Dis. 2025 Apr 5;16(1):254. [Abstract]
- Int J Biol Macromol. 2024 Sep 15:135698. [Abstract]
- Free Radic Biol Med. 2024 Jun 19:S0891-5849(24)00531-8. [Abstract]
- Oncogene. 2025 May;44(16):1078-1092. [Abstract]
- J Med Chem. 2020 Jul 23;63(14):7633-7652. [Abstract]
- Cell Mol Life Sci. 2022 Jun 28;79(7):387. [Abstract]
- Biochem Pharmacol. 2025 Aug 28;242(Pt 1):117287. [Abstract]
- J Med Virol. 2025 Oct;97(10):e70655. [Abstract]
- J Med Virol. 2024 Jan;96(1):e29372. [Abstract]
- Antiviral Res. 2026 Jun:250:106413. [Abstract]
- J Virol. 2025 Nov 25;99(11):e0098525. [Abstract]
- Viruses. 2021 Jun 28;13(7):1255. [Abstract]
- BMC Cancer. 2024 Jun 25;24(1):761. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2026 Apr 15:1274:124971. [Abstract]
- Res Sq. 2026 Jun 15.
- bioRxiv. 2026 May 18.
- bioRxiv. 2026 May 6.
- Res Sq. 2025 Jul 18.
- bioRxiv. 2025 Mar 2:2025.02.26.640463. [Abstract]
- Research Square Preprint. 2020 Dec.
-
Bio/Physico-chemical Assay
-
Microbiological Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
8.1 μM
Compound: Breq
|
Antiproliferative activity against human A375 cells for 24 hrs by MTT assay
Antiproliferative activity against human A375 cells for 24 hrs by MTT assay
|
[PMID: 24929289] |
| BXPC-3 | IC50 |
0.94 μM
Compound: Brequinar Sodium
|
Cytotoxicity against human BxPC3 cells assessed as decrease in cell proliferation after 72 hrs by MTT reduction assay
Cytotoxicity against human BxPC3 cells assessed as decrease in cell proliferation after 72 hrs by MTT reduction assay
|
10.1039/C6MD00179C |
| HCT-116 | IC50 |
0.158 μM
Compound: Brequinar Sodium
|
Cytotoxicity against human HCT116 cells assessed as decrease in cell proliferation after 72 hrs by MTT reduction assay
Cytotoxicity against human HCT116 cells assessed as decrease in cell proliferation after 72 hrs by MTT reduction assay
|
10.1039/C6MD00179C |
| Hep 3B2 | IC50 |
10.22 μM
Compound: Breq
|
Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay
Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay
|
[PMID: 24929289] |
| HT-29 | IC50 |
13.98 μM
Compound: Brequinar sodium
|
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 30738663] |
| MDA-MB-231 | IC50 |
12.45 μM
Compound: Brequinar sodium
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 30738663] |
| WI-38 | IC50 |
33.954 μM
Compound: Brequinar Sodium
|
Cytotoxicity against human WI38 cells assessed as decrease in cell proliferation after 72 hrs by MTT reduction assay
Cytotoxicity against human WI38 cells assessed as decrease in cell proliferation after 72 hrs by MTT reduction assay
|
10.1039/C6MD00179C |
Potent and selective DHODH inhibitors
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 96201-88-6
-
Appearance Solid
-
Molecular Weight 397.35
-
Formula C23H14F2NNaO2
-
Color White to off-white
-
SMILES
O=C(C1=C(C)C(C2=CC=C(C3=CC=CC=C3F)C=C2)=NC4=CC=C(F)C=C14)O[Na]
-
Synonyms
DuP785 sodium; NSC 368390 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (34)
-
Journal Impact Factor
-
Most Recent
-
Nature
2024 Feb;626(7998):411-418. PMID: 38297130
Brequinar sodium purchased from MedChemExpress. Usage Cited in: Nature. 2024 Feb;626(7998):411-418. [Abstract]
Mitochondrial lipid peroxidation assessment of HT1080 treated with RSL3 (0.5 μM) and BQR (Brequinar 200 μM) for 2 h after pretreatment of 7-DHC (25 μM) and Fer-1 for 24 h.
-
Nature
2022 Apr;604(7904):134-140. PMID: 35130559
Brequinar sodium purchased from MedChemExpress. Usage Cited in: Nature. 2022 Apr;604(7904):134-140. [Abstract]
Anti-SARS2 activity of Brequinar (0-10 μM, 1 h pretreatment and infected for 40-48 h).
Brequinar sodium purchased from MedChemExpress. Usage Cited in: Nature. 2022 Apr;604(7904):134-140. [Abstract]
Lungs analyzed for viral titer by plaque assay. Wild type Balb/C mice were treated with Brequinar (IP) and/or molnupiravir (EIDD-2801) (PO) daily at the indicated concentrations starting 24 h after infection. Mice (N = 5 mice per group) were intranasally inoculated with 1×10^5 PFU/mouse of SARS-CoV-2/B.1.351.
Brequinar sodium purchased from MedChemExpress. Usage Cited in: Nature. 2022 Apr;604(7904):134-140. [Abstract]
Lungs quantified for interstitial inflammation. Wild type Balb/C mice were treated with Brequinar (IP) and/or molnupiravir (EIDD-2801) (PO) daily at the indicated concentrations starting 24 h after infection. Mice (N = 5 mice per group) were intranasally inoculated with 1×10^5 PFU/mouse of SARS-CoV-2/B.1.351.
Brequinar sodium purchased from MedChemExpress. Usage Cited in: Nature. 2022 Apr;604(7904):134-140. [Abstract]
Lungs fixed in 4% PFA for H&E staining (Scale bar = 200 μm). Wild type Balb/C mice were treated with Brequinar (IP) and/or molnupiravir (EIDD-2801) (PO) daily at the indicated concentrations starting 24 h after infection. Mice (N = 5 mice per group) were intranasally inoculated with 1×10^5 PFU/mouse of SARS-CoV-2/B.1.351.
-
Nat Cell Biol
De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence. [Abstract]2023 Jun;25(6):836-847. PMID: 37291265 -
-
Adv Sci (Weinh)
2026 Jun;13(33):e21098. PMID: 41933927 -
Adv Sci (Weinh)
Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy. [Abstract]2022 May 4;e2105451. PMID: 35508804 -
J Adv Res
Antimycin A inhibits alpha-herpesvirus replication by disrupting the formation of pyrimidinosomes. [Abstract]2025 May 10:S2090-1232(25)00309-1. PMID: 40354935 -
Sci Adv
2025 Aug 15;11(33):eadx6587. PMID: 40815641 -
Sci Adv
Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor-mediated synergistic antileukemic actions. [Abstract]2022 Sep 16;8(37):eabp9005. PMID: 36112677 -
Redox Biol
Enteric coronavirus PDCoV evokes a non-Warburg effect by hijacking pyruvic acid as a metabolic hub. [Abstract]2024 May:71:103112. PMID: 38461791 -
Redox Biol
17β-oestradiol inhibits ferroptosis in the hippocampus by upregulating DHODH and further improves memory decline after ovariectomy. [Abstract]2023 Jun:62:102708. PMID: 37116254 -
Cell Rep Med
Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis. [Abstract]2025 Jan 27:101928. PMID: 39879992 -
Nat Struct Mol Biol
RNAi screens identify HES4 as a regulator of redox balance supporting pyrimidine synthesis and tumor growth. [Abstract]2024 May 20. PMID: 38769389 -
J Colloid Interface Sci
Dual metabolic reprogramming by metal-polyphenol nanoplatform enhances ferroptotic therapy for triple-negative breast cancer. [Abstract]2026 Jul 15:714:140204. PMID: 41780429 -
Cell Death Dis
Inhibition of mitochondrial complex I induces mitochondrial ferroptosis by regulating CoQH2 levels in cancer. [Abstract]2025 Apr 5;16(1):254. PMID: 40185704 -
Int J Biol Macromol
circE2F1-encoded peptide inhibits circadian machinery essential for nucleotide biosynthesis and tumor progression via repressing SPIB/E2F1 axis. [Abstract]2024 Sep 15:135698. PMID: 39288851 -
Free Radic Biol Med
Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]2024 Jun 19:S0891-5849(24)00531-8. PMID: 38906233 -
Oncogene
The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation. [Abstract]2025 May;44(16):1078-1092. PMID: 39865175 -
J Med Chem
Bifunctional Naphtho[2,3- d][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects In Vitro and In Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production. [Abstract]2020 Jul 23;63(14):7633-7652. PMID: 32496056 -
Cell Mol Life Sci
Vitamin K1 inhibits ferroptosis and counteracts a detrimental effect of phenprocoumon in experimental acute kidney injury. [Abstract]2022 Jun 28;79(7):387. PMID: 35763128 -
Biochem Pharmacol
Flubendazole inhibits cervical carcinoma by targeting DHODH to induce ferroptosis and mitophagy. [Abstract]2025 Aug 28;242(Pt 1):117287. PMID: 40885318 -
J Med Virol
Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]2025 Oct;97(10):e70655. PMID: 41117261 -
J Med Virol
Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus. [Abstract]2024 Jan;96(1):e29372. PMID: 38235544 -
Antiviral Res
Broad-spectrum antiviral screening reveals pyrimidine biosynthesis as a target for inhibiting measles virus replication. [Abstract]2026 Jun:250:106413. PMID: 41967510 -
J Virol
African swine fever virus hijacks host pyrimidine metabolism to promote viral replication. [Abstract]2025 Nov 25;99(11):e0098525. PMID: 41171159 -
Viruses
Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. [Abstract]2021 Jun 28;13(7):1255. PMID: 34203149 -
BMC Cancer
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement. [Abstract]2024 Jun 25;24(1):761. PMID: 38918775 -
J Chromatogr B Analyt Technol Biomed Life Sci
Deficiency in beclin1 alleviates doxorubicin-induced liver injury through inhibiting ferroptosis and autophagy. [Abstract]2026 Apr 15:1274:124971. PMID: 41707439 -
-
-
-
-
bioRxiv
Pathway Coessentiality Mapping Reveals Complex II is Required for de novo Purine Biosynthesis in Acute Myeloid Leukemia. [Abstract]2025 Mar 2:2025.02.26.640463. PMID: 40060603 -
Solvent & Solubility
DMSO : 31.25 mg/mL (78.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (248 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5167 mL | 12.5834 mL | 25.1667 mL | 62.9168 mL |
| 5 mM | 0.5033 mL | 2.5167 mL | 5.0333 mL | 12.5834 mL | |
| 10 mM | 0.2517 mL | 1.2583 mL | 2.5167 mL | 6.2917 mL | |
| 15 mM | 0.1678 mL | 0.8389 mL | 1.6778 mL | 4.1945 mL | |
| 20 mM | 0.1258 mL | 0.6292 mL | 1.2583 mL | 3.1458 mL | |
| 25 mM | 0.1007 mL | 0.5033 mL | 1.0067 mL | 2.5167 mL | |
| 30 mM | 0.0839 mL | 0.4194 mL | 0.8389 mL | 2.0972 mL | |
| 40 mM | 0.0629 mL | 0.3146 mL | 0.6292 mL | 1.5729 mL | |
| 50 mM | 0.0503 mL | 0.2517 mL | 0.5033 mL | 1.2583 mL | |
| 60 mM | 0.0419 mL | 0.2097 mL | 0.4194 mL | 1.0486 mL |